However, due to the pleiotropic effects of factors such as CXCL8 and the phenotypic diversity of TANs, caution must be exercised when testing CXCR1/2 inhibitors to prevent unexpected toxicity.212 Most studies indicate that CXCR1/2 inhibitors are generally safe, but some clinical trials have revealed that CXCR2 inhibitors, such as AZD5069, can lead to reduced blood neutrophil counts in patients with chronic obstructive pulmonary disease.213 Therefore, achieving optimal dosing and duration of CXCR2 inhibitors is crucial for effective management. The gene discussed is CXCR2; the disease is chronic obstructive pulmonary disease.